• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of jbacterPermissionsJournals.ASM.orgJournalJB ArticleJournal InfoAuthorsReviewers
J Bacteriol. Jul 1996; 178(14): 4157–4165.
PMCID: PMC178173

A new type of conjugative transposon encodes resistance to sulfamethoxazole, trimethoprim, and streptomycin in Vibrio cholerae O139.

Abstract

Vibrio cholerae O139 is the first non-O1 serogroup of V. cholerae to give rise to epidemic cholera. Apparently, this new serogroup arose from an El Tor O1 strain of V cholerae, but V. cholerae O139 is distinguishable from V. cholerae El Tor O1 by virtue of its novel antigenic structure and also its characteristic pattern of resistances to the antibiotics sulfamethoxazole, trimethoprim, streptomycin, and furazolidone. We found that the first three of these antibiotic resistances are carried on an approximately 62-kb self-transmissible, chromosomally integrating genetic element which we have termed the SXT element. This novel conjugative transposon-like element could be conjugally transferred from V. cholerae O139 to V cholerae O1 and Escherichia coli strains, where it integrated into the recipient chromosomes in a site-specific manner independent of recA. To study the potential virulence properties of the SXT element as well as to improve upon the live attenuated O139 vaccine strain Bengal-2, a large internal deletion in the SXT element was crossed on to the Bengal-2 chromosome. The resulting strain, Bengal-2.SXT(s), is sensitive to sulfamethoxazole and trimethoprim and colonizes the intestines of suckling mice as well as wild-type strains do, suggesting that the SXT element does not encode a colonization factor. Derivatives of Bengal-2.SXT(s) are predicted to be safe, antibiotic-sensitive, live attenuated vaccines for cholera due to the O139 serogroup.

Full Text

The Full Text of this article is available as a PDF (754K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Albert MJ, Siddique AK, Islam MS, Faruque AS, Ansaruzzaman M, Faruque SM, Sack RB. Large outbreak of clinical cholera due to Vibrio cholerae non-O1 in Bangladesh. Lancet. 1993 Mar 13;341(8846):704–704. [PubMed]
  • Bik EM, Bunschoten AE, Gouw RD, Mooi FR. Genesis of the novel epidemic Vibrio cholerae O139 strain: evidence for horizontal transfer of genes involved in polysaccharide synthesis. EMBO J. 1995 Jan 16;14(2):209–216. [PMC free article] [PubMed]
  • Butterton JR, Beattie DT, Gardel CL, Carroll PA, Hyman T, Killeen KP, Mekalanos JJ, Calderwood SB. Heterologous antigen expression in Vibrio cholerae vector strains. Infect Immun. 1995 Jul;63(7):2689–2696. [PMC free article] [PubMed]
  • Calia KE, Murtagh M, Ferraro MJ, Calderwood SB. Comparison of Vibrio cholerae O139 with V. cholerae O1 classical and El Tor biotypes. Infect Immun. 1994 Apr;62(4):1504–1506. [PMC free article] [PubMed]
  • Clewell DB, Flannagan SE, Jaworski DD. Unconstrained bacterial promiscuity: the Tn916-Tn1545 family of conjugative transposons. Trends Microbiol. 1995 Jun;3(6):229–236. [PubMed]
  • Comstock LE, Maneval D, Jr, Panigrahi P, Joseph A, Levine MM, Kaper JB, Morris JG, Jr, Johnson JA. The capsule and O antigen in Vibrio cholerae O139 Bengal are associated with a genetic region not present in Vibrio cholerae O1. Infect Immun. 1995 Jan;63(1):317–323. [PMC free article] [PubMed]
  • Coster TS, Killeen KP, Waldor MK, Beattie DT, Spriggs DR, Kenner JR, Trofa A, Sadoff JC, Mekalanos JJ, Taylor DN. Safety, immunogenicity, and efficacy of live attenuated Vibrio cholerae O139 vaccine prototype. Lancet. 1995 Apr 15;345(8955):949–952. [PubMed]
  • Donnenberg MS, Kaper JB. Construction of an eae deletion mutant of enteropathogenic Escherichia coli by using a positive-selection suicide vector. Infect Immun. 1991 Dec;59(12):4310–4317. [PMC free article] [PubMed]
  • Ferro-Novick S, Honma M, Beckwith J. The product of gene secC is involved in the synthesis of exported proteins in E. coli. Cell. 1984 Aug;38(1):211–217. [PubMed]
  • Gerbaud G, Dodin A, Goldstein F, Courvalin P. Genetic basis of trimethoprim and O/129 resistance in Vibrio cholerae. Ann Inst Pasteur Microbiol. 1985 Nov-Dec;136B(3):265–273. [PubMed]
  • Goldberg I, Mekalanos JJ. Effect of a recA mutation on cholera toxin gene amplification and deletion events. J Bacteriol. 1986 Mar;165(3):723–731. [PMC free article] [PubMed]
  • Herrington DA, Hall RH, Losonsky G, Mekalanos JJ, Taylor RK, Levine MM. Toxin, toxin-coregulated pili, and the toxR regulon are essential for Vibrio cholerae pathogenesis in humans. J Exp Med. 1988 Oct 1;168(4):1487–1492. [PMC free article] [PubMed]
  • Iredell JR, Manning PA. Biotype-specific tcpA genes in Vibrio cholerae. FEMS Microbiol Lett. 1994 Aug 1;121(1):47–54. [PubMed]
  • Jesudason MV, John TJ. Transferable trimethoprim resistance of Vibrio cholerae O1 encountered in southern India. Trans R Soc Trop Med Hyg. 1990 Jan-Feb;84(1):136–137. [PubMed]
  • Karaolis DK, Lan R, Reeves PR. The sixth and seventh cholera pandemics are due to independent clones separately derived from environmental, nontoxigenic, non-O1 Vibrio cholerae. J Bacteriol. 1995 Jun;177(11):3191–3198. [PMC free article] [PubMed]
  • Matsushita S, Kudoh Y, Ohashi M. Transferable resistance to the vibriostatic agent 2,4-diamino-6,7-diisopropyl-pteridine (O/129) in Vibrio cholerae. Microbiol Immunol. 1984;28(10):1159–1162. [PubMed]
  • Mekalanos JJ. Live bacterial vaccines: environmental aspects. Curr Opin Biotechnol. 1994 Jun;5(3):312–319. [PubMed]
  • Mekalanos JJ, Sadoff JC. Cholera vaccines: fighting an ancient scourge. Science. 1994 Sep 2;265(5177):1387–1389. [PubMed]
  • Mekalanos JJ, Swartz DJ, Pearson GD, Harford N, Groyne F, de Wilde M. Cholera toxin genes: nucleotide sequence, deletion analysis and vaccine development. Nature. 1983 Dec 8;306(5943):551–557. [PubMed]
  • Miller VL, Mekalanos JJ. A novel suicide vector and its use in construction of insertion mutations: osmoregulation of outer membrane proteins and virulence determinants in Vibrio cholerae requires toxR. J Bacteriol. 1988 Jun;170(6):2575–2583. [PMC free article] [PubMed]
  • Nair GB, Bag PK, Shimada T, Ramamurthy T, Takeda T, Yamamoto S, Kurazono H, Takeda Y. Evaluation of DNA probes for specific detection of Vibrio cholerae O139 Bengal. J Clin Microbiol. 1995 Aug;33(8):2186–2187. [PMC free article] [PubMed]
  • Nair GB, Ramamurthy T, Bhattacharya SK, Mukhopadhyay AK, Garg S, Bhattacharya MK, Takeda T, Shimada T, Takeda Y, Deb BC. Spread of Vibrio cholerae O139 Bengal in India. J Infect Dis. 1994 May;169(5):1029–1034. [PubMed]
  • Nair GB, Shimada T, Kurazono H, Okuda J, Pal A, Karasawa T, Mihara T, Uesaka Y, Shirai H, Garg S, et al. Characterization of phenotypic, serological, and toxigenic traits of Vibrio cholerae O139 bengal. J Clin Microbiol. 1994 Nov;32(11):2775–2779. [PMC free article] [PubMed]
  • Popovic T, Fields PI, Olsvik O, Wells JG, Evins GM, Cameron DN, Farmer JJ, 3rd, Bopp CA, Wachsmuth K, Sack RB, et al. Molecular subtyping of toxigenic Vibrio cholerae O139 causing epidemic cholera in India and Bangladesh, 1992-1993. J Infect Dis. 1995 Jan;171(1):122–127. [PubMed]
  • Ramamurthy T, Garg S, Sharma R, Bhattacharya SK, Nair GB, Shimada T, Takeda T, Karasawa T, Kurazano H, Pal A, et al. Emergence of novel strain of Vibrio cholerae with epidemic potential in southern and eastern India. Lancet. 1993 Mar 13;341(8846):703–704. [PubMed]
  • Ramamurthy T, Pal A, Pal SC, Nair GB. Taxonomical implications of the emergence of high frequency of occurrence of 2,4-diamino-6,7-diisopropylpteridine-resistant strains of Vibrio cholerae from clinical cases of cholera in Calcutta, India. J Clin Microbiol. 1992 Mar;30(3):742–743. [PMC free article] [PubMed]
  • Rhine JA, Taylor RK. TcpA pilin sequences and colonization requirements for O1 and O139 vibrio cholerae. Mol Microbiol. 1994 Sep;13(6):1013–1020. [PubMed]
  • Salyers AA, Shoemaker NB, Li LY. In the driver's seat: the Bacteroides conjugative transposons and the elements they mobilize. J Bacteriol. 1995 Oct;177(20):5727–5731. [PMC free article] [PubMed]
  • Tacket CO, Losonsky G, Nataro JP, Comstock L, Michalski J, Edelman R, Kaper JB, Levine MM. Initial clinical studies of CVD 112 Vibrio cholerae O139 live oral vaccine: safety and efficacy against experimental challenge. J Infect Dis. 1995 Sep;172(3):883–886. [PubMed]
  • Tschäpe H, Tietze E, Koch C. Characterization of conjugative R plasmids belonging to the new incompatibility group IncU. J Gen Microbiol. 1981 Nov;127(1):155–160. [PubMed]
  • Waldor MK, Colwell R, Mekalanos JJ. The Vibrio cholerae O139 serogroup antigen includes an O-antigen capsule and lipopolysaccharide virulence determinants. Proc Natl Acad Sci U S A. 1994 Nov 22;91(24):11388–11392. [PMC free article] [PubMed]
  • Waldor MK, Mekalanos JJ. Emergence of a new cholera pandemic: molecular analysis of virulence determinants in Vibrio cholerae O139 and development of a live vaccine prototype. J Infect Dis. 1994 Aug;170(2):278–283. [PubMed]
  • Waldor MK, Mekalanos JJ. ToxR regulates virulence gene expression in non-O1 strains of Vibrio cholerae that cause epidemic cholera. Infect Immun. 1994 Jan;62(1):72–78. [PMC free article] [PubMed]
  • Waldor MK, Mekalanos JJ. Vibrio cholerae O139 specific gene sequences. Lancet. 1994 May 28;343(8909):1366–1366. [PubMed]
  • Yam WC, Yuen KY, Wong SS, Que TL. Vibrio cholerae O139 susceptible to vibriostatic agent 0/129 and co-trimoxazole. Lancet. 1994 Aug 6;344(8919):404–405. [PubMed]

Articles from Journal of Bacteriology are provided here courtesy of American Society for Microbiology (ASM)

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...